Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELEV Elevation Oncology	$0.38 +0.4%	$0.33	$0.22 ▼ $3.45	$22.61M	1.43	1.50 million shs	771,286 shs
JATT JATT Acquisition	$1.22 -3.2%	$1.21	$7.80 ▼ $12.38	$21.05M	N/A	41,322 shs	391,454 shs
PLRZ Polyrizon	$0.84 -22.0%	$59.63	$0.55 ▼ $1,200.00	$4.45M	N/A	1.50 million shs	1.73 million shs
SNYR Synergy CHC Corp. (Uplisting)	$2.08 -9.2%	$2.01	$0.12 ▼ $10.00	$19.12M	N/A	625,584 shs	51,017 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELEV Elevation Oncology	+0.18%	+24.61%	+8.94%	-28.64%	-88.68%
JATT JATT Acquisition	-1.56%	+6.78%	+1.61%	+16.67%	-67.10%
PLRZ Polyrizon	+33.75%	+26.42%	-84.98%	-99.24%	+106,999,900.00%
SNYR Synergy CHC Corp. (Uplisting)	+9.05%	+22.46%	+21.42%	-35.49%	+228,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELEV Elevation Oncology	3.3897 of 5 stars	4.0	5.0	0.0	0.0	1.6	1.7	0.6
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNYR Synergy CHC Corp. (Uplisting)	3.9295 of 5 stars	3.8	0.0	0.0	0.0	3.3	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELEV Elevation Oncology	2.00	Hold	$3.39	787.01% Upside
JATT JATT Acquisition	0.00	N/A	N/A	N/A
PLRZ Polyrizon	0.00	N/A	N/A	N/A
SNYR Synergy CHC Corp. (Uplisting)	3.50	Strong Buy	$10.00	380.77% Upside

Current Analyst Ratings Breakdown

Latest PLRZ, SNYR, JATT, and ELEV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/10/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral
6/9/2025	ELEV Elevation Oncology	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/9/2025	ELEV Elevation Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/24/2025	ELEV Elevation Oncology	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$5.00 ➝ $1.00
3/21/2025	ELEV Elevation Oncology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
3/21/2025	ELEV Elevation Oncology	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$9.00 ➝ $1.00
3/21/2025	ELEV Elevation Oncology	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/21/2025	ELEV Elevation Oncology	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$10.00 ➝ $0.70
3/21/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $1.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.29 per share	N/A
JATT JATT Acquisition	N/A	N/A	$0.05 per share	27.08	($0.53) per share	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	N/A	N/A
SNYR Synergy CHC Corp. (Uplisting)	$33.59M	0.57	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELEV Elevation Oncology	-$45.70M	-$0.82	N/A	N/A	N/A	N/A	-59.73%	-40.05%	8/5/2025 (Estimated)
JATT JATT Acquisition	$6.85M	N/A	0.00	∞	N/A	N/A	-49.58%	2.84%	N/A
PLRZ Polyrizon	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SNYR Synergy CHC Corp. (Uplisting)	N/A	N/A	0.00	3.53	N/A	N/A	N/A	N/A	N/A

Latest PLRZ, SNYR, JATT, and ELEV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ELEV Elevation Oncology	-$0.20	-$0.24	-$0.04	-$0.24	N/A	N/A
5/15/2025	Q1 2025	SNYR Synergy CHC Corp. (Uplisting)	$0.07	$0.10	+$0.03	$0.10	$9.03 million	$8.17 million
3/31/2025	Q4 2024	SNYR Synergy CHC Corp. (Uplisting)	$0.10	$0.01	-$0.09	$0.01	$10.55 million	$10.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	N/A
SNYR Synergy CHC Corp. (Uplisting)	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELEV Elevation Oncology	0.45	17.77	17.77
JATT JATT Acquisition	N/A	0.15	0.15
PLRZ Polyrizon	N/A	N/A	N/A
SNYR Synergy CHC Corp. (Uplisting)	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELEV Elevation Oncology	83.70%
JATT JATT Acquisition	47.97%
PLRZ Polyrizon	N/A
SNYR Synergy CHC Corp. (Uplisting)	N/A

Insider Ownership

Company	Insider Ownership
ELEV Elevation Oncology	8.10%
JATT JATT Acquisition	20.00%
PLRZ Polyrizon	N/A
SNYR Synergy CHC Corp. (Uplisting)	56.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELEV Elevation Oncology	40	59.22 million	54.33 million	Optionable
JATT JATT Acquisition	3	17.25 million	13.80 million	Not Optionable
PLRZ Polyrizon	N/A	5.33 million	N/A	N/A
SNYR Synergy CHC Corp. (Uplisting)	40	9.19 million	N/A	N/A

PLRZ, SNYR, JATT, and ELEV Headlines

Recent News About These Companies

Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Jack Ross Buys 9,400 Shares

June 12 at 9:37 AM | insidertrades.com

New to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink's Global Expansion

June 10 at 12:18 PM | guardonline.com

Synergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Help Drive FOCUSfactor Energy Drink Global Expansion

June 10 at 8:00 AM | globenewswire.com

Synergy CHC Announces New $20 Million Long-Term Credit Facility

June 4, 2025 | globenewswire.com

Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Jack Ross Buys 5,000 Shares

May 22, 2025 | insidertrades.com

Synergy CHC Corp. Announces First Quarter 2025 Earnings and Conference Call Information

May 1, 2025 | globenewswire.com

Synergy CHC Stock Short Interest Report | NASDAQ:SNYR | Benzinga

April 17, 2025 | benzinga.com

Synergy CHC Reports its Eighth Consecutive Quarter of Profitability and its Fourth Quarter and Full Year 2024 Financial Results

March 31, 2025 | markets.businessinsider.com

Synergy CHC Corp. Announces Fourth Quarter and Full Year 2024 Earnings and Conference Call Information

March 21, 2025 | markets.businessinsider.com

Roth MKM Initiates Coverage of Synergy CHC (SNYR) with Buy Recommendation

January 22, 2025 | msn.com

Synergy CHC Announces 7th Quarter of Profitability

December 7, 2024 | markets.businessinsider.com

Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Purchases $2,700,000.00 in Stock

October 25, 2024 | insidertrades.com

Synergy CHC Corp. Announces Closing of Initial Public Offering

October 24, 2024 | globenewswire.com

Synergy CHC Corp. Prices $10.35 Million Initial Public Offering

October 22, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ, SNYR, JATT, and ELEV Company Descriptions

Elevation Oncology NASDAQ:ELEV

$0.38 +0.00 (+0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$0.38 +0.00 (+0.08%)

As of 04:02 PM Eastern

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

JATT Acquisition NYSE:JATT

$1.22 -0.04 (-3.17%)

As of 06/12/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

Polyrizon NASDAQ:PLRZ

$0.84 -0.24 (-21.96%)

As of 04:00 PM Eastern

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

Synergy CHC Corp. (Uplisting) NASDAQ:SNYR

$2.08 -0.21 (-9.17%)

As of 04:00 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time